Dushyanth Surakanti Founder & CEO of Sparta Biomedical Testimonial

Sparta Biomedical and bioaccess®: Advancing Osteoarthritis Treatment Through Innovation

Osteoarthritis affects millions of people worldwide, limiting mobility and quality of life. Enter Sparta Biomedical, a company founded in 2019 with a mission to transform osteoarthritis treatment by commercializing an innovative technology developed at Duke University. This groundbreaking solution replicates native hyaline cartilage, offering new hope to patients suffering from this debilitating condition.

Sparta Biomedical has navigated a complex path of regulatory and manufacturing challenges to bring its technology to market. Now, the company is on the brink of a major milestone—filing for regulatory approval to conduct clinical studies in both the United States and Colombia.

To achieve this, Sparta Biomedical chose to partner with bioaccess®, a trusted contract research organization (CRO) with deep expertise in managing first-in-human medical device studies, particularly in countries like Colombia. bioaccess’s robust infrastructure, experienced medical staff, and commitment to transparent communication made them the ideal partner to support Sparta’s ambitious goals.

The partnership has exceeded expectations. The bioaccess® team has been praised for their strong medical expertise, proactive approach, and ability to anticipate Sparta’s needs—qualities that are rare among CROs. This collaboration has positioned Sparta Biomedical to advance its mission of revolutionizing osteoarthritis treatment.

Want to know more about this exciting collaboration and the technology behind it? Watch the full testimonial and learn how bioaccess® is playing a vital role in supporting medical innovation and improving patient outcomes in Colombia and beyond.